Bone Marrow Transplantation in Acute Leukemia

Schaefer, U. W.; Beelen, Dietrich W.; Mahmoud, Hossam K.; Quabeck, K.; Becher, R.; Schmidt, C. G.; Bamberg, M.; Quast, Ulrich; Haralambie, E.; Linzenmeier, G; Stollmann, B.; Grosse‐Wilde, H.; Richter, Hans; Hantschke, D.; Henneberg, K.; Luboldt, W

doi:10.1007/978-3-642-71213-5_31

Cited by 6 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…V3890 Sgr had nova eruptions in 1962 and 1990, reaching a peak magnitude of V=8.1 mag with t 3 = 14 days. Again, with detailed measures of the original plates and comparison stars as well as a collection of all existing eruption data, I find that the two eruptions had identical light curves (Schaefer 2009). In quiescence, I measure the average brightness and colors to be R=14.3, B-V=0.9, and V-R=1.2 mag.…”

Section: V3890 Sgrmentioning

confidence: 85%

“…V745 Sco had nova eruptions in 1937 and 1989, reaching a peak magnitude of V=9.4 mag and the time from the peak until the light curve had declined by three magnitudes (t 3 ) is 9 days. After my modern photometry of comparison star magnitudes, remeasuring the outburst brightnesses on the original archival plates, and collecting all existing data, I conclude that the eruption light curve was identical for both events (Schaefer 2009). In quiescence, I measured average magnitudes and colors to be R=15.5, B-V=1.9, V-R=2.6 mag.…”

Section: V745 Scomentioning

confidence: 90%

“…With our discovery that V2487 Oph (Nova Oph 1998) had a 'second' nova eruption in 1900 (Pagnotta, Schaefer, & Xiao 2008), there are now ten known RNe in our own galaxy (Schaefer 2009). The single most important parameter of any cataclysmic variable system is the orbital period, P orb .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Orbital Periods for Three Recurrent Novae

Schaefer

2009

ApJ

View full text Add to dashboard Cite

I report on the discovery of the orbital periods of three recurrent novae in our galaxy. V745 Sco has an orbital period of 510 ± 20 days with ellipsoidal modulations, based on SMARTS photometry from 2004-2008. V3890 Sgr has an orbital period of 519.7 ± 0.3 days with ellipsoidal modulations and a shallow eclipse, based primarily on SMARTS and AAVSO photometry from 1995-2008, but also extending back to 1899 with archival plates. In addition, a sinusoidal modulation of amplitude 0.2 mag and period 103.8 ± 0.4 days is seen mainly in the red, with this attributed to ordinary pulsations in the giant companion star. V394 CrA has an orbital period equal to twice its primary photometric period (P orb = 1.515682 ± 0.000008 days), as based on photometry extending from 1989-2008. I use all available information (including the UBVRIJHK spectral energy distributions) to get distances to the four RNe with red giant companions as 800 ± 140 pc for T CrB, 4300 ± 700 pc for RS Oph, 7300 ± 1200 pc for V745 Sco, and 6000 ± 1000 pc for V3890 Sgr. Further, the red giant in the RS Oph system has a mass loss rate of close to 3.7 × 10 −8 M ⊙ yr −1 as based on many confident measures, and this is too weak (by a factor of 100,000) to supply the white dwarf with mass at the known rate of 3.9 × 10 −6 M ⊙ yr −1 . Thus, the only way to get matter onto the white dwarf fast enough is through Roche lobe overflow, and this confidently demonstrates that the distance to RS Oph is 3000 pc.

show abstract

Section: V3890 Sgrmentioning

confidence: 85%

Section: V745 Scomentioning

confidence: 90%

See 1 more Smart Citation

Orbital Periods for Three Recurrent Novae

Schaefer

2009

ApJ

View full text Add to dashboard Cite

show abstract

“…30,31 In most, fractionated total-body irradiation plus cyclophosphamide or busulfan plus cyclophosphamide were part of the conditioning therapy. Parenteral nutrition with glucose, amino acids, and lipids (calorie intake 35 kcal/kg BW/d) was supplemented by water-and fat-soluble vitamins including 200 IU of ergocalciferol (vitamin D 2 ).…”

Section: Cytostatic Chemotherapy Preparative Regimens and Gvhd Propmentioning

confidence: 99%

Bone loss following hematopoietic stem cell transplantation: a long-term follow-up

Schulte

Beelen

2004

Blood

106

View full text Add to dashboard Cite

Transplantation-associated bone loss is a well-known phenomenon, however, effects of hematopoietic stem cell transplantation are insufficiently characterized. We conducted a prospective, unicentric, longterm follow-up in 280 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Bone mineral density (BMD) was measured before transplantation and then yearly for at least 4 years. Patients received vitamin D plus calcium until steroid withdrawal. Mean baseline BMD was normal. We demonstrated significant bone loss with nadir BMD at month 6 for the spine and at month 24 for total body and femoral neck. Average annual bone loss was 0.6% for spine, 0.4% for total body, 2.3% for femoral neck, and 3.5% for Ward triangle. While spine and total body BMD returned to baseline, bone loss at femoral neck sites was attenuated, but BMD did not return to baseline until month 48 (P < . IntroductionOrgan transplant recipients benefit from greatly improved survival, however, long-term complications such as osteoporosis and osteoporotic fractures 1 adversely affect life quality and therefore have to be addressed. Transplantation of solid organs such as heart, 2 kidney, 3 liver, 4 and lung 5 is associated with rapid bone loss and increased susceptibility to osteoporotic fragility fractures. Transplantation-associated bone loss has been demonstrated to occur preferentially during the first year after transplantation, 6-8 with at least partial recovery during further follow-up. 9 Data on the temporal sequence of bone loss in long-term survivors following hematopoietic stem cell transplantation (HSCT) are sparse. 10-13 However, these patients are exposed to numerous bone toxic factors: induction and consolidation therapy of the underlying hematological disease; malignancy-related changes in bone structure, especially in acute leukemia 14 ; dose-dependent toxicity of high-dose chemotherapy to bone marrow osteoprogenitors 15 ; conditioning regimen for transplantation, including total body irradiation (TBI) 16 ; graftversus-host disease (GVHD) and its treatment with steroids and cyclosporine A 17 ; immobilization; and hypogonadism following TBI. Cross-sectional studies of bone loss after HSCT revealed conflicting data: 5 of 25 patients, examined at least one year after HSCT (mean, 3; range, 1-10 years) showed osteoporotic bone mineral density (BMD) 18 ; 29 long-term survivors with a median survival of 5 years (minimum, 3 years) showed BMD within normal limits (Z-score Ͼ Ϫ1.5) except 2 male patients with hypogonadism. 19 Prospective studies of bone loss are sparse; [10][11][12][13][20][21][22] the study with longest observation time presents follow-up of 11 patients observed for 3 years. 13 Data demonstrate rapid bone loss during the first 6 months after transplantation (5.7% at the lumbar spine and 6.9% to 8.7% at the femoral neck sites) with no further decline between months 6 and 12 21 and even recovery of bone mass during further follow-up. 10,12,13,22 Ebeling 11 first evaluated likely mechanisms for bone loss in ...

show abstract

“…Owing to the involvement of the salivary and lacrimal glands, the majority of patients with disseminated cGVHD develop sicca syndrome. 7 In addition to the subjective complaints, patients with salivary gland dysfunction are susceptible to increased caries, oral pain, frequent infections and difficulties in speaking, chewing and swallowing. These difficulties may lead to inadequate nutrition and a decline in quality of life.…”

Section: Introductionmentioning

confidence: 99%

Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD)

Agha‐Hosseini

Mirzaii‐Dizgah

Ghavamzadeh

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/ day orally for 7 days, and 15 patients with placebo. Unstimulated whole saliva was collected in the morning on four occasions (30 min before pilocarpine or placebo intake, and 1 h, 1 day and 7 days after the first intake). Significantly, higher salivary flow rates, and sodium and total protein outputs were observed in the second samples of pilocarpine-treated patients compared with controls, whereas calcium and IgA outputs were not altered. Changes in these parameters were not significant in the third and fourth samples, although they were higher in the pilocarpine group. Patients who had received pilocarpine expressed satisfaction with their treatment. These data suggest that pilocarpine may improve salivary flow rate and the feeling of xerostomia in patients with cGVHD.

show abstract

Bone Marrow Transplantation in Acute Leukemia

Cited by 6 publications

References 7 publications

Orbital Periods for Three Recurrent Novae

Orbital Periods for Three Recurrent Novae

Bone loss following hematopoietic stem cell transplantation: a long-term follow-up

Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD)

Contact Info

Product

Resources

About